Download to read offline
AlphaBioCom
- 2. AlphaBioCom is the scientific communication powerhouse that delivers your most precious assets with precision, integrity, and passion Confidential – Not for Distribution
- 3. Inside AlphaBioCom • Global capability • US and UK facilities • Strength in experience • Exclusively in-house team All have at least 4 years experience All have PhDs Full service • We create, refine and communicate value for your assets Confidential – Not for Distribution
- 4. Therapeutic Expertise • Autoimmune Disease • Neuroscience/ • Cardiovascular Neuropsychology • Dermatology • Obstetrics/Gynecology • Endocrinology • Oncology • Gastroenterology • Pain Management • Genetics • Pulmonology/Respiratory Disease • Gynecology • Renal and Urology • Immunology • Rheumatology • Infectious Disease • Virology • Metabolic Confidential – Not for Distribution
- 5. Experience Across theProduct Life Experience into our 7th Year Cycle Phase I Phase II Phase III Product Launch Phase IV • ORALGAM • ORALGAM • CERVISTA • ADIANA • AVODART • ACHN-490 • ACHN-490 • CERVARIX • NOVASURE • ADIANA • ACHN-750 • MENHIBRIX • ULORIC • CERVISTA • BACTROBAN • ACHN ESA • Nano Assets • LA HPV TEST • CERVARIX • NOVASURE • Nano assets • MENHIBRIX • ULORIC • CERVISTA • MONOPREP • HAVRIX • CERVARIX • RESLIZUMAB • PEDIARIX • FLUVIRIN • IXIARO • TWINRIX • PEDIARIX • CERVISTA • IXIARO • OPTAFLU • TWINRIX • FLUAD • HAVRIX • AVODART • NAPROXEN • DICLOFENAC • INDOCIN • ULORIC • RYTHMOL SR • ALTABAX Confidential – Not for Distribution • LOVAZA
- 6. Scientific Communication Service Scientific communication planning Scientific communication development and execution Thought Leader identification and engagement Confidential – Not for Distribution
- 7. Scientific communication planning? •Systematic approach to ensuring that you reach your audience with the right data, information at the right time with the right frequency to create a change in understanding and/or awareness – AlphaBioCom
- 8. Planning cycle Objectives Strategy Objectives Strategy Measurement Objectives Objectives Strategy Strategy Audience Measurement Audience Measurement Audience Measurement Audience Execution Messages Execution Channels Messages Channels Execution Messages Execution Channels Messages Channels
- 9. Objectives Strategy Measurement Audience Objectives Execution Messages Channels • Visualize, characterize and state the shift that you aim to create Awareness Beliefs Knowledge
- 10. Objectives Strategy Measurement Audience Strategy Execution Messages Channels • Intelligent Approach – Understanding and managing Issues and Objectives • Driven by advanced SWOT analysis • Affirmative issues to assert advantages • Barriers and disadvantages to weigh and balance – Route to success • Clear defined roadmap to achieve goals
- 11. Objectives Strategy Measurement Audience Audience Execution Messages Channels Who do we need How do we define to communicate and describe with? them? How will we know How do we we have communicate communicated with them? effectively?
- 12. Objectives Strategy Measurement Audience Scientific Message Execution Messages Channels • Core communication Tier1 points • Primary scientific evidence • Evidence based Tier 2 medicine • Health Economics and Outcomes Research • Benefits and attributes Tier 3 from literature. • Reviews and supporting clinical trials
- 13. Objectives Strategy Measurement Audience Scientific Channel Considerations Execution Messages Channels Interactive Journals Congresses tools Impact Time On-Line Journals Specialty Web based Audience interactive publications Time Interruptive media Acceptance Company Apps Acceptance
- 14. Objectives Strategy Measurement Audience Execution Execution Messages Channels Situation analysis Delve into science Identify plan framework Research authors Populate content and finalize plan Execute deliverables in line with plan framework Review and refine
- 15. Objectives Strategy Measurement Audience Precision Processes Execution Messages Channels • Strict adherence to policies • Clear defined training and QA procedures • Proven development processes – Abstracts – Posters – Oral presentations – Manuscripts • Data Management and Integrity – Communications trail – Audited processes • Precise project reporting • How do you manage these processes?
- 16. Objectives Strategy Measurement Audience Planning & Measurement Execution Messages Channels What When How • results • cyclical • set and versus • before measure key objectives • during performance • milestones indicators • after versus plans
- 17. Objectives Strategy Measurement Audience Planning & Measurement Execution Messages Channels ID Task Name Duration Start Finish Jan Feb March April May June July 1 Program 106 days Wed Jan 28, ‘09 Wed Jan 24, ‘09 2 Research 10 days Wed Jan 28, ‘09 Tues Feb 10, ’09 Writer Call w/ author and create Author/Writer 3 5 days Wed Feb 11, ‘09 Tues Feb 17, ’09 outline 4 Expanded outline to client 15 days Wed Feb 18, ’09 Tues Mar 10, ’09 Writer 5 Client comments on outline 10 days Wed Mar 11, ’09 Tues Mar 24, ’09 Client 6 Expanded outline to authors 10 days Wed Mar 25, ’09 Tues April 7, ’09 Writer 7 Authors comments to ABC 10 days Wed April 8, ’09 Tues April 21, ’09 Author Client comments on 1st draft to Client 8 5 days Wed April 22, ’09 Tues April 28, ’09 ABC 9 Draft 1 to author 10 days Wed April 29, ’09 Tues May 12, ’09 Writer 10 Author review of Draft 1 10 days Wed May 13, ’09 Tues May 26, ’09 Author 11 Draft 2 to authors and Client 5 days Wed May 27, ’09 Tues Jun 2, ‘09 Writer Client/ 12 All comments due to ABC 5 days Wed Jun 3, ’09 Tues Jun 9, ‘09 Author Final draft to authors and 13 5 days Wed Jun 10, ’09 Tues Jun 16, ‘09 Writer Client All comments and final Client/ 14 5 days Wed Jun 17, ’09 Tues Jun 23, ‘09 Author approval due 15 Writer Confidential – Not for Distribution day Submission 1 Wed Jun 24, ‘09 Wed Jun 24, ‘09
- 18. Objectives Strategy Measurement Audience Planning & Measurement Execution Messages Channels Project Estimated Project # Start Status Variance Comments Name Finish ADV01 Case Study 12/27/09 3/13/10 On Track Waiting for data Awaiting data from ADV02 Abstract PKPD 11/23/09 1/10/10 +10 days Clinical Faculty presentation ADV03 Symposia 12/3/09 5/9/10 +5 days catch up plan in place Primary On target for first ADV04 12/6/09 6/20/10 On Track Manuscript draft ADV05 Ad Board 3/16/10 10/23/10 On Track Creating advisor list On Track Caution Off Track Variance +/- 5 days Variance 5-10 days off Variance + 10 days Confidential – Not for Distribution
- 19. Publication Powerhouse AlphaBioCom broadest publication experience • Published in over 100 journals • Across 20 different therapeutic categories • Spanning US, Eu and International journals • Working with more 500 authors • Located in 10 different countries • Yet we demand that every single paper receives the same precision, integrity and passion as our first!
- 20. Clients Clients Our ….Partners Confidential – Not for Distribution
- 21. Precision, Integrity andPassion in our 7th year Scientific • 19 plans Communication Plans Scientific • >250 scientific manuscripts Communication • >100 congress submissions (abstracts, posters) Deliverables • >200 scientific presentations • 70 advisory boards TL/KOL • 25 TL education programs
- 22. Performance Indicators: Precision, Integrity and Passion in numbers. Scientific • 100% approved and implemented Communication Plans • >90% acceptance first journal Scientific submitted Communication • 100% all journal submissions Deliverables • >98% acceptance first congress
- 23. Power in theNegative • Zero manuscripts rejected due to poor quality writing • Never cited for inaccuracies or data management error by any client • Never cited for a process compliance issue by any client • Never had to withdraw any deliverable due to error • Never failed a client audit • Zero citations in any newspaper • Evidence our processes are robust and work
- 24. Contact Information Stephen Douthwaite President and Chief Strategist 2 Radnor Corporate Center, Suite 200 100 Matsonford Road Radnor, PA 19087 (610) 225-0400 stephend@alphabiocom.com Confidential – Not for Distribution